Kisspeptin for women is still a research topic, not a treatment: no kisspeptin product is approved for fertility, missed periods or low desire. In small UK studies, a single kisspeptin-54 injection matured eggs during IVF in 95% of women at high risk of ovarian hyperstimulation, with no moderate or severe cases of that complication.[5] Its effect depends heavily on cycle timing: one injection raised LH by about 20.6 IU/L just before ovulation but only about 0.1 IU/L early in the cycle.[1]
This guide covers what kisspeptin does in the female body and what human studies found for IVF, missed periods, PCOS and sexual desire. For the compound itself, see our kisspeptin-10 profile; for doses, see kisspeptin dosage; and for approved options, see peptides for fertility and the sexual health peptides hub.
How kisspeptin works in the female body
Kisspeptin is made in the hypothalamus, a part of the brain that controls hormones. It switches on GnRH, which tells the pituitary to release LH and FSH, the hormones that grow follicles (the fluid sacs that hold eggs) and trigger ovulation.[4] People with mutations that switch off kisspeptin signaling are infertile.[4]
Researchers use two forms. Kisspeptin-54 is the main form in blood and was used in nearly all the women’s treatment studies. Kisspeptin-10 is a short fragment and is the form FDA has reviewed for compounding.[4][17]
Your cycle changes the response
Women respond to kisspeptin very differently from men, and from one week of the cycle to the next.
| Situation | What happened |
|---|---|
| Early cycle (follicular phase), kisspeptin-54 | LH rose by about 0.1 IU/L[1] |
| After ovulation (luteal phase), kisspeptin-54 | LH rose by about 2.2 IU/L[1] |
| Just before ovulation, kisspeptin-54 | LH rose by about 20.6 IU/L[1] |
| Early cycle, kisspeptin-10 (London) | No LH rise, even at high doses[2] |
| Early cycle, kisspeptin-10 (Edinburgh) | Modest LH rise at a low dose[3] |
| After menopause, kisspeptin-10 | Largest LH and FSH rise of any group[3] |
| Combined birth control pill, kisspeptin-10 | No significant LH rise[3] |
The pattern fits kisspeptin’s natural role in the mid-cycle LH surge, and it means a dose that seems to do nothing at one time of the month can act strongly at another.[1][3]
Kisspeptin as an IVF trigger
During IVF, a “trigger shot” finishes egg maturation before eggs are collected. IVF can lead to ovarian hyperstimulation syndrome (OHSS), a potentially life-threatening complication.[5] Researchers at Imperial College London tested kisspeptin-54 as a trigger:
- 53 women undergoing IVF: a single injection matured eggs at every dose tested. Embryos were transferred in 92% of women, and 23% had a clinical pregnancy.[4]
- 60 women at high risk of OHSS: eggs matured in 95%. Per embryo transfer, the clinical pregnancy rate was 53% and the live birth rate 45%. No woman developed moderate, severe or critical OHSS.[5]
- 62 women at high risk of OHSS: a second kisspeptin dose 10 hours after the first raised the share of women with a good egg yield from 45% to 71%, without more moderate OHSS.[6]
These studies were small and mostly compared doses with each other rather than with hCG. The authors themselves called for direct comparisons with established triggers.[6]
Missed periods (hypothalamic amenorrhea)
Hypothalamic amenorrhea, one of the most common causes of lost periods in women of reproductive age, happens when the brain’s pulses of reproductive hormones slow down.[9] Kisspeptin acts at the top of that chain, so researchers have tested it here:
- Twice-daily injections: in women with hypothalamic amenorrhea, kisspeptin-54 injections caused a strong LH rise on day 1 that faded almost completely by day 14. Women still responded to GnRH, and ultrasound measures of the ovaries did not change.[7]
- Twice-weekly injections: spacing doses out caused only partial loss of response, and hormone levels were still raised after 8 weeks compared with saline. No adverse effects were observed.[8]
- IV infusion: in 5 women, a steady infusion tripled the number of LH pulses, the natural rhythm that is missing in this condition, though the best dose differed from woman to woman.[9]
None of these studies tested whether periods or fertility returned long-term.
PCOS and prolactin-related missed periods
- PCOS: in a pilot study of 12 women with polycystic ovary syndrome who were not ovulating, twice-daily kisspeptin-54 injections for 21 days caused a small LH rise. Two women grew a dominant follicle and ovulated, one grew a follicle without ovulating, and most showed no follicle response. Some of the work was funded by a drug company, Ferring.[11]
- High prolactin: in 2 French women whose periods had stopped because of prolactin-secreting pituitary tumors, a 12-hour kisspeptin-10 infusion restarted LH pulses and raised ovarian hormones.[10]
Low sexual desire
In a UK trial, 32 premenopausal women with hypoactive sexual desire disorder (persistent, distressing low desire) each received a 75-minute IV infusion of kisspeptin-54 and a placebo. Kisspeptin changed activity in brain areas involved in sexual and attraction processing while the women watched erotic videos and viewed faces. It was well tolerated, with no reported adverse effects.[14]
That is a brain-imaging result after a single infusion, not proof that desire improves with ongoing use. For other options, see our PT-141 profile and best peptides for sexual health.
Newer forms: nasal spray and MVT-602
- Nasal spray: in a 2025 study, kisspeptin-54 sprayed into the nose raised LH in healthy women and in women with hypothalamic amenorrhea, and no adverse events were reported.[15]
- MVT-602: a lab-made kisspeptin receptor activator. In healthy women, its LH rise peaked later and lasted longer than after kisspeptin-54, and it also raised LH in women with PCOS or hypothalamic amenorrhea.[12] In a trial of 75 women given mild ovarian stimulation, a single injection produced an LH surge similar to the natural one, and ovulation within 5 days occurred in 75% to 100% of women on MVT-602, depending on dose, versus 60% on placebo. It was well tolerated at all doses.[13]
Neither is approved.
Safety and what is unknown
- Short-term: most women’s studies reported kisspeptin as well tolerated.[8][14][15]
- Cycle changes: in a small study of healthy women (5 per group), a week of twice-daily kisspeptin-54 injections did not stop their cycles, but cycles were about 2 days shorter than with saline and the LH peak came earlier.[16]
- Long-term and pregnancy: no study followed women for months, and we found no pregnancy safety data outside IVF trials.
- Products sold online: FDA lists kisspeptin-10 among compounding substances that may pose significant safety risks, citing possible immune reactions and little safety information.[17]
Questions to ask a clinician
- What is causing my irregular or missed periods, and has my prolactin been checked?
- Which approved fertility treatments fit my situation?
- If I am doing IVF and at risk of OHSS, what trigger options does my clinic use?
- Am I eligible for a kisspeptin research study?
- For low desire, which approved treatments or therapies should I consider?
This is general information, not medical advice.
